Target TSH Levels in Patients with Differentiated Thyroid Cancer

Estratification by Risk and Response to Treatment

The American Joint Committee on Cancer recommends maintaining TSH in the low-normal range (0.5-2 mIU/L) in all patients with excellent response to treatment and in low-risk patients with incomplete or indeterminate biochemical responses 1, 2, 3
The National Comprehensive Cancer Network suggests that this target minimizes the risks of cardiovascular and bone-related complications associated with prolonged TSH suppression, especially in elderly patients and postmenopausal women 4
The European Thyroid Association recommends considering mild TSH suppression (0.1-0.5 mIU/L) in intermediate- to high-risk patients with incomplete or indeterminate biochemical responses to treatment 1, 2, 3

The National Comprehensive Cancer Network warns that prolonged TSH suppression increases the risk of cardiac arrhythmias, bone demineralization, and overt thyrotoxicosis symptoms 4
Patients with chronically suppressed TSH levels should receive counseling to ensure adequate daily intake of calcium (1200 mg/day) and vitamin D (1000 units/day) 4

The American Thyroid Association recommends monitoring TSH every 6-8 weeks while titrating hormone replacement therapy 6
Once adequately treated, tests should be repeated every 6-12 months or if symptoms change 6
Free T4 can help interpret persistently abnormal TSH levels during therapy, as TSH may take longer to normalize 6

The European Thyroid Association suggests that in patients who have been disease-free for several years, regardless of their initial risk class, therapy with levothyroxine can be changed from suppressive to replacement 5
Patients who remain disease-free for several years will likely be able to maintain their TSH levels within the reference range 4